You have activated a Bronze+ WP Symposium feature, but you have not entered your Activation Code. Get one on the Membership page on the WP Symposium website.

Living theragenomics: Dangers of codeine and tramadol medicines in children

April 23, 2017 – This is a Safety Announcement from April 20, 2017, by the American Food & Drug Administration (FDA) to the fact that FDA further restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children and recommends against their use in breastfeeding women. This

Read more ›

Posted in Adverse Drug Reaction [ADR], Allelic Variant, Children, New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , ,

Open source pharma: A gem for patients?

April 22, 2017 – An open source pharma roadmap: This is the title of a conceptual paper just published by Balasegaram M, et. al., in the open access journal PLoS Medicine (2017) 14(4), freely accessible to everybody here. The essay outlines how open source methods of working could be applied

Read more ›

Posted in On The Horizon, Thasso Post, Theragenomic Medicine
Tags: , ,

A giant leap in direct-to-consumer theragenomics (DTCT)

Just April 07, 2017 – Yesterday’s date marks a giant leap into the new area of direct-to-consumer theragenomics (DTCT) in that the American Food & Drug Administration (FDA) has allowed the marketing of the first direct-to-consumer Genetic Health Risk (GHR) tests that provide genetic risk information for certain conditions. These tests

Read more ›

Posted in Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , ,

Children: Is there personalized medicine for children too?

April 04, 2017 – Personalized medicine, also referred to as precision medicine, incorporates the individual patient’s characteristics into treatment, rather than relying on population means. Over the past several years, it has become a significant focus for research. Developments in pharmacogenomics, the study of genomic variations that influence response to drugs,

Read more ›

Posted in Allelic Variant, Children, Genetic Background, In The Press, On The Horizon, Pediatrics, Thasso Post, Theragenomic Medicine
Tags: , , , ,

A price for women’s beauty: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)

March 27, 2017 – We all adore the beauty of women. Some women may feel that they need some help from medical practice to become the most  beautiful. When it comes to corrective breast implants, the price may be very high in some rare cases, where women develop breast implant-associated

Read more ›

Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , , ,

SEMA4D gene variant quadruples obesity risk in individuals of African descent

March 26, 2017 – There is ample evidence that the burden of obesity is not the same across ethnic groups. While diet and lifestyle play a large role in determining body weight, there is also a heritable component. Unfortunately,  most prior studies that have evaluated the role of genes in obesity have

Read more ›

Posted in Allelic Variant, Genetic Predisposition, New Research, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , ,

Face2Gene: tool using facial recognition, AI and genetic big data to improve rare disease diagnosis and treatment

March 25, 2017 – The Boston-based start up company FDNA has launched an app-based tool for clinicians using facial recognition, artificial intelligence (AI) and genetic big data to improve rare disease diagnosis and treatment. If it were not for an incredible achievement of merging top notch sience from engineering to artificial

Read more ›

Posted in eHealth, Genetic Background, In The Press, New Research, On The Horizon, Rare Diseases, Thasso Post, Theragenomic Medicine
Tags: , , , , , ,

Avelumab (Bavencio) approved to treat Merkel Cell Carcinoma (MCC)

March 24, 2017 –  Merkel Cell Carcinoma (MCC) is a rare and highly aggressive form of skin cancer, which, in most cases, is caused by the Merkel Cell Polyomavirus (MCV). So far, patients with diagnosed MCC did not have an approved treatment option. This has dramatically changed with the announcement by the American Food

Read more ›

Posted in New Drug Approval, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , ,

Polygenic hazard scores in age-associated Alzheimer’s disease

March 23, 2017 – For sure across the United States, but by a fair assumption worldwide also, late-onset Alzheimer’s disease (AD) is the most common form of dementia. There is a strong need for in vivo markers for AD risk stratification and cohort enrichment in therapeutic trials and eventually in the

Read more ›

Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, New Research, On The Horizon, Thasso Post, Theragenomic Medicine
Tags: , , , , , , ,

Risk of severe if not fatal skin reactions with Pembrolizumab (Keytruda)

March 21, 2017 – Health Canada just communicated this important safety information: Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) under treatment of patients with Pembrolizumab (Keytruda) have been reported internationally in the clinical trials and post-marketing setting. There were 8 cases of SJS (1 of them with

Read more ›

Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , , , ,

thasso post magazine

View my Flipboard Magazine.

follow thasso

Facebooktwittergoogle_pluslinkedinrssyoutubeby feather

subscribe to thasso

By signing up, you agree to our Terms of Service and Privacy Policy.

calendar

April 2017
M T W T F S S
« Mar    
 12
3456789
10111213141516
17181920212223
24252627282930

categories

archive

tweets